Biotechgate Global Database ›
Trading in Novo Nordisk shares by board members, executives and associated persons on 3-4 February 2021
Bagsværd, Denmark, 5 February 2021 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
Members of Executive Management have in 2017 participated in a long-term incentive programme consisting of a one-year performance period (2017) and a three-year vesting period (2018-2020). The shares allocated after the one-year performance period (2017) have been locked up for a three-year period. The number of shares has not subsequently been reduced by the Board as the financial performance in the vesting period reached specified threshold levels. Hence, the original number of shares allocated after the one-year performance period has on 3 February 2021 been transferred to current and former executives as specified below. No dividend has been paid to the executives during the one-year performance period or the three-year vesting period.
The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons.
Please find below a statement of such trading in shares issued by Novo Nordisk.
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Lars Fruergaard Jørgensen | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | President and CEO | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) | Description of the financial instrument, type of instrument, | Shares | |||
| Identification code | Novo Nordisk B DK0060534915 | ||||
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with long-term incentive programme) | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 0.00 | 43,850 shares | ||||
| d) | Aggregated information
| 43,850 shares DKK 0.00 | |||
| e) | Date of the transaction | 2021-02-03 | |||
| f) | Place of the transaction | Outside a trading venue | |||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Lars Fruergaard Jørgensen | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | President and CEO | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) | Description of the financial instrument, type of instrument, | Shares | |||
| Identification code | Novo Nordisk B DK0060534915 | ||||
| b) | Nature of the transaction | Sale of shares | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 450.60 | 22,000 shares | ||||
| d) | Aggregated information
| 22,000 shares DKK 450.60 | |||
| e) | Date of the transaction | 2021-02-04 | |||
| f) | Place of the transaction | Nasdaq Copenhagen | |||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Maziar Mike Doustdar | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Executive vice president, International Operations | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) | Description of the financial instrument, type of instrument, | Shares | |||
| Identification code | Novo Nordisk B DK0060534915 | ||||
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with long-term incentive programme) | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 0.00 | 15,281 shares | ||||
| d) | Aggregated information
| 15,281 shares DKK 0.00 | |||
| e) | Date of the transaction | 2021-02-03 | |||
| f) | Place of the transaction | Outside a trading venue | |||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Karsten Munk Knudsen | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Executive vice president, Chief Financial Officer | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) | Description of the financial instrument, type of instrument, | Shares | |||
| Identification code | Novo Nordisk B DK0060534915 | ||||
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with long-term incentive programme) | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 0.00 | 6,750 shares | ||||
| d) | Aggregated information
| 6,750 shares DKK 0.00 | |||
| e) | Date of the transaction | 2021-02-03 | |||
| f) | Place of the transaction | Outside a trading venue | |||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Doug Langa | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Executive vice president, North America Operations | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) | Description of the financial instrument, type of instrument, | Shares | |||
| Identification code | Novo Nordisk B DK0060534915 | ||||
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with long-term incentive programme) | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 0.00 | 8,215 shares | ||||
| d) | Aggregated information
| 8,215 shares DKK 0.00 | |||
| e) | Date of the transaction | 2021-02-03 | |||
| f) | Place of the transaction | Outside a trading venue | |||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Doug Langa | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Executive vice president, North America Operations | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) | Description of the financial instrument, type of instrument, | Shares | |||
| Identification code | Novo Nordisk B DK0060534915 | ||||
| b) | Nature of the transaction | Sale of shares | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 448.48 | 8,215 shares | ||||
| d) | Aggregated information
| 8,215 shares DKK 448.48 | |||
| e) | Date of the transaction | 2021-02-04 | |||
| f) | Place of the transaction | Nasdaq Copenhagen | |||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Camilla Sylvest | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Executive vice president, Commercial Strategy & Corporate Affairs | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) | Description of the financial instrument, type of instrument, | Shares | |||
| Identification code | Novo Nordisk B DK0060534915 | ||||
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with long-term incentive programme) | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 0.00 | 6,037 shares | ||||
| d) | Aggregated information
| 6,037 shares DKK 0.00 | |||
| e) | Date of the transaction | 2021-02-03 | |||
| f) | Place of the transaction | Outside a trading venue | |||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Mads Krogsgaard Thomsen | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Executive vice president, Chief Science Officer | |||
| b) |
By: GlobeNewswire
- 05 Feb 2021
Return to news
Partners
Upcoming Life Sciences Events
| ||||
